ABUS
Arbutus Biopharma Corp
4.30$
-4.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -2.7% | -1.1% | +0.3% | -5.6% | -0.9% | -0.9% | -96.7% | +0.0% | +0.0% | +0.0% | +0.0% | – | |
| – | -30.6% | +16.9% | +57.9% | -32.1% | -24.4% | +118.4% | -75.8% | +46.2% | -0.1% | +7.7% | +19.6% | – | |
| – | – | -292.3% | – | -190.6% | – | – | -446.2% | – | +56.3% | -9,993.3% | – | – | |
| – | -60.4% | +650.3% | -98.9% | -59.0% | +20,875.6% | -100.0% | – | +0.0% | +300.0% | +202,749,900.0% | -26.6% | – | |
| – | +113.1% | -47.4% | -15.9% | -221.9% | – | -15.4% | +37.6% | -164.2% | -86.4% | – | -175.5% | – | |
| – | +126.5% | +541.7% | -0.2% | -92.7% | -19.9% | +95.9% | -83.7% | +86.3% | +94.3% | +608.5% | -72.9% | – | |
| – | – | +92.1% | +17.1% | -257.2% | – | -83.4% | -55.0% | -4,565.5% | – | – | -179.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.